Table 1 Baseline characteristics by patient group (nintedanib, non-nintedanib, and surveillance)
From: Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
Parameters (Mean) | Nintedanib (N = 9) | Non-nintedanib (N = 6) | Surveillance (N = 6) | P value |
|---|---|---|---|---|
Age (years) | 53 ± 24 | 60 ± 13 | 55 ± 15 | NS |
Female | 4 (44%) | 2 (33%) | 5 (83%) | NS |
Smoking history | NS | |||
Never smoker | 5 | 1 | 5 | |
Ex- smoker | 4 | 4 | 1 | |
Current smoker | 0 | 1 | 0 | |
BMI (kg/m2) | 17.61 ± 2.21 | 20.79 ± 3.1 | 20.64 ± 2.82 | NS |
Clubbing (No) | 9 (100%) | 6 (100%) | 6 (100%) | NS |
Platythorax (yes) | 5 (55%) | 4 (66%) | 3 (50%) | NS |
Idiopathic (yes) | 7 (77%) | 5 (83%) | 5 (83%) | NS |
ANA + | 3 (33%) | 4 (66%) | 4 (66%) | NS |
Tested for mutation (yes) | 4 (44%) | 3 (50%) | 4 (66%) | NS |
TERT + | 0 (0%) | 1 (16%) | 2 (33%) | NS |
FVC (%) | 50 ± 20 | 57 ± 18 | 72 ± 23 | NS |
FEV1/FVC | 0.87 ± 0.07 | 0.87 ± 0.09 | 0.97 ± 0.08 | NS |
TLC (%) | 63 ± 17 | 68 ± 14 | 75 ± 25 | NS |
RV/TLC (%) | 166 ± 57 | 123 ± 24 | 112 ± 22 | NS |
DLCO % | 46 ± 19 | 59 ± 18 | 48 ± 13 | NS |
KCO % | 83 ± 24 | 72 ± 9 | 81 ± 13 | NS |
Tracheal surface (mm) | 397 ± 108* | 367 ± 93 | 211 ± 53 | 0.009 |
Lower lobes UIP on HRCT/pathology | 3 (33%) | 0 (0%) | 2 (33%) | NS |